Responsibility to bronchodilatator and glucocorticosteroid in patients with bronchiectasia and reversible airflow limitation

Journal of Jilin University Medicine Edition

Volumn 32, Issue 5, 2006, Pages 872-875

  Ding, Hui ^a   Wang, Jian Guo ^a   Sun, Xiao Yan ^a   Xu, Li Jun ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Adrenergic beta agonists; Bronchiectasis; Glucocorticoids; Reversible airflow limitation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BRONCHIECTASIS; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFECTION CONTROL; LENGTH OF STAY; LUNG FUNCTION; MALE; PEAK EXPIRATORY FLOW; RESPIRATORY AIRFLOW; SPUTUM ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 33750160423     PISSN: 1671587X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Chinese source. 2004: 35.
2. Chinese source. 2001.
3. Hassan JA, Saadiah S, Roslanh H, et al. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs inpatients with bronchiectasis [J]. Respirology, 1999, 4: 423-426.
4. Chinese source. 2004, 3 (5): 304-307.
5. Chinese source. 2004, 30 (3): 459-461.
6. Chinese source. 2005, 31 (1): 149-151.
7. Tsang KW, Tan KC, Ho P L. Inhaled fluticasone in bronchiectasis: a 12-month study [J]. Thorax 2005, 60: 239-243.